Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/upadacitinib-versus-placebo-or-adalimumab-in-patients-with-rheumatoid-YkPHPPqx9R
References (53)
-
R. Westhovens, P. Taylor, R. Alten, D. Pavlova, F. Enríquez-Sosa, M. Mazur, M. Greenwald, A. Aa, F. Vanhoutte, Chantal Tasset, Pille Harrison (2016)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)Annals of the Rheumatic Diseases, 76
-
B. Fautrel, B. Granger, B. Combe, A. Saraux, F. Guillemin, X. Loet (2012)
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohortArthritis Research & Therapy, 14
-
R. Vollenhoven, R. Vollenhoven, S. Ernestam, P. Geborek, I. Petersson, L. Cöster, E. Waltbrand, A. Zickert, J. Theander, Ake Thorner, H. Hellstrom, A. Teleman, C. Dackhammar, F. Akre, K. Forslind, L. Ljung, R. Oding, A. Chatzidionysiou, M. Wornert, J. Bratt (2009)
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trialThe Lancet, 374
-
I. Scott, S. Hider, D. Scott (2018)
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?Drug Safety, 41
-
R. Vollenhoven, R. Fleischmann, S. Cohen, E. Lee, J. Meijide, Sylke Wagner, Š. Forejtová, S. Zwillich, D. Gruben, T. Koncz, G. Wallenstein, S. Krishnaswami, J. Bradley, B. Wilkinson (2012)
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.The New England journal of medicine, 367 6
-
W. Chung, Chiao‐Ling Peng, Cheng-Li Lin, Yen-Jung Chang, Yung-fu Chen, J. Chiang, F. Sung, C. Kao (2013)
Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort studyAnnals of the Rheumatic Diseases, 73
-
J. Smolen, G. Burmester, B. Combe, J. Curtis, S. Hall, B. Haraoui, R. Vollenhoven, C. Cioffi, C. Ecoffet, L. Gervitz, L. Ionescu, L. Peterson, R. Fleischmann (2016)
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyThe Lancet, 388
-
(2018)
A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX‐naïve patients with active rheumatoid arthritis [abstract] -
M. Genovese, R. Fleischmann, B. Combe, S. Hall, A. Rubbert-Roth, Ying Zhang, Yijie Zhou, M. Mohamed, S. Meerwein, A. Pangan (2018)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialThe Lancet, 391
-
J. Kalden, H. Schulze-Koops (2017)
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatmentNature Reviews Rheumatology, 13
-
P. Taylor, J. Kremer, P. Emery, S. Zuckerman, G. Ruotolo, J. Zhong, Lei Chen, S. Witt, Chadi Saifan, M. Kurzawa, J. Otvos, M. Connelly, W. Macias, D. Schlichting, Terence Rooney, S. Bono, I. McInnes (2018)
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studiesAnnals of the Rheumatic Diseases, 77
-
J. Smolen, R. Landewé, J. Bijlsma, G. Burmester, K. Chatzidionysiou, M. Dougados, J. Nam, S. Ramiro, M. Voshaar, R. Vollenhoven, D. Aletaha, M. Aringer, M. Boers, C. Buckley, F. Buttgereit, V. Bykerk, M. Cardiel, B. Combe, M. Cutolo, Y. Eijk-Hustings, P. Emery, A. Finckh, C. Gabay, J. Gómez-Reino, L. Gossec, J. Gottenberg, J. Hazes, T. Huizinga, M. Jani, D. Karateev, M. Kouloumas, T. Kvien, Zhanguo Li, X. Mariette, I. McInnes, E. Mysler, P. Nash, K. Pavelka, G. Poór, C. Richez, P. Riel, A. Rubbert-Roth, K. Saag, J. Silva, T. Stamm, T. Takeuchi, R. Westhovens, M. Wit, D. Heijde (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases, 76
-
G. Wells, J. Becker, J. Teng, M. Dougados, M. Schiff, J. Smolen, D. Aletaha, P. Riel (2008)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rateAnnals of the Rheumatic Diseases, 68
-
J. Brazier, R. Harper, N. Jones, A. O’Cathain, Kate Thomas, T. Usherwood, L. Westlake (1992)
Validating the SF-36 health survey questionnaire: new outcome measure for primary care.British Medical Journal, 305
-
J. Smolen, A. Pangan, P. Emery, W. Rigby, Yoshiya Tanaka, J. Vargas, Ying Zhang, N. Damjanov, A. Friedman, A. Othman, H. Camp, S. Cohen (2019)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 studyThe Lancet, 393
-
F. Salaffi, G. Giacobazzi, M. Carlo (2018)
Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets—A Focus on the JAK-STAT PathwayPain Research & Management, 2018
-
G. Burmester, R. Landewé, M. Genovese, A. Friedman, N. Pfeifer, N. Varothai, A. Lacerda (2016)
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 76
-
(2009)
National Cancer Institute: National Institutes of Health. Common terminology criteria for adverse events version 4.0 -
L. Klareskog, D. Heijde, J. Jager, A. Gough, J. Kalden, M. Malaise, E. Mola, K. Pavelka, J. Sany, L. Settas, J. Wajdula, R. Pedersen, S. Fatenejad, M. Sanda (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 363
-
E. Keystone, A. Kavanaugh, J. Sharp, H. Tannenbaum, Y. Hua, L. Teoh, S. Fischkoff, E. Chartash (2004)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.Arthritis and rheumatism, 50 5
-
Jasvinder Singh, K. Saag, S. Bridges, E. Akl, R. Bannuru, M. Sullivan, E. Vaysbrot, Christine McNaughton, M. Osani, R. Shmerling, Jeffrey Curtis, Daniel Furst, D. Parks, Arthur Kavanaugh, James O'dell, Charles King, Amye Leong, E. Matteson, J. Schousboe, B. Drevlow, Seth Ginsberg, J. Grober, E. Clair, Elizabeth Tindall, Amy Miller, Kelly Clayton, R. Crow‐Hercher, Shantana Hazel, Brittney Johnson, Leslie Rott, Whitney White, C. Wiedmeyer, V. Montori, W. Nowell, Kaleb Michaud, L. Davis, Brian Sauer, E. Solow, A. Reimold, Pascale Schwab, Joshua Baker (2015)
American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis -
J. Singh, K. Saag, S. Bridges, E. Akl, R. Bannuru, M. Sullivan, E. Vaysbrot, Christine McNaughton, M. Osani, R. Shmerling, J. Curtis, D. Furst, D. Parks, A. Kavanaugh, J. O'dell, Charles King, Amye Leong, E. Matteson, J. Schousboe, B. Drevlow, S. Ginsberg, J. Grober, E. St.clair, E. Tindall, Amy Miller, T. McAlindon (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care & Research, 68
-
M. Mohamed, A. Nader, Insa Winzenborg, Eva Doelger, P. Noertersheuser, A. Pangan, A. Othman (2019)
FRI0138 EXPOSURE-RESPONSE ANALYSES OF UPADACITINIB EFFICACY AND SAFETY IN RHEUMATOID ARTHRITIS – ANALYSES OF PHASE 2 AND 3 STUDIESAnnals of the Rheumatic Diseases, 78
-
Thasia Woodworth, D. Furst, R. Alten, Clifton Bingham, David Yocum, Victor Sloan, Wayne Tsuji, Randall Stevens, James Fries, James Witter, Kent Johnson, M. Lassere, Peter Brooks (2007)
Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.The Journal of rheumatology, 34 6
-
G. Burmester, J. Kremer, F. Bosch, A. Kivitz, L. Bessette, Yihan Li, Yijie Zhou, A. Othman, A. Pangan, H. Camp (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 391
-
M. Dougados, D. Heijde, Ying-Chou Chen, M. Greenwald, E. Drescher, Jiajun Liu, S. Beattie, S. Witt, I. Torre, C. Gaich, Terence Rooney, D. Schlichting, S. Bono, P. Emery (2016)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD studyAnnals of the Rheumatic Diseases, 76
-
J. Fries, P. Spitz, D. Young (1982)
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.The Journal of rheumatology, 9 5
-
G. Kaeley, A. Evangelisto, Midori Nishio, S. Goss, Shufang Liu, J. Kalabic, H. Kupper (2016)
Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA TrialThe Journal of Rheumatology, 43
-
R. Fleischmann, E. Mysler, S. Hall, A. Kivitz, R. Moots, Zhen Luo, R. Demasi, K. Soma, Richard Zhang, L. Takiya, S. Tatulych, C. Mojcik, S. Krishnaswami, S. Menon, J. Smolen, L. Adams, M. Ally, Maria Plooy, I. Louw, Savithree Nayiager, Christoffel Nel, D. Nel, H. Reuter, Ahmed Soloman, C. Spargo, M. Rischmueller, Shunil Sharma, R. Will, P. Youssef, C. Arroyo, Rosario Baes, Roger Dulos, Llewellyn Hao, Allan Lanzon, J. Lichauco, J. Mangubat, E. Ramiterre, B. Reyes, P. Tan, J. Choe, Y. Kang, S. Kwon, Sang-Heon Lee, Shin-Seok Lee, D. Yoo, Hsiao-Yi Lin, S. Luo, S. Tsai, W. Tsai, Jui-Cheng Tseng, Cheng-chung Wei, P. Asavatanabodee, K. Nantiruj, S. Nilganuwong, P. Uea-areewongsa, L. Majstorović, S. Bacic, A. Batalov, Gabriela Georgieva-Slavcheva, M. Mihailova, N. Nikolov, D. Penev, Y. Spasov, K. Stanimirova, Stoyan Todorov, A. Toncheva, N. Yordanova, Z. Mosterova, Libor Novosád, L. Procházková, Helena Stehlikova, Z. Stejfova, N. Kiseleva, Lea Pank, Triin Savi, Balbir-Gurman Alexandra, H. Amital, D. Mevorach, I. Rosner, A. Mihailova, Evija Stumbra-Stumberga, Vida Basijokiene, Virginija Lietuvininkiene, D. Unikiene, J. Brzezicki, A. Dudek, M. Glowacka-Kulesz, Barbara Grabowicz-Wasko, Sabina Hajduk-Kubacka, J. Hilt, P. Hrycaj, S. Jeka, R. Kolasa, M. Krogulec, Hanna Mastalerz, Anna Olak-Popko, E. Owczarek, Z. Ruzga, A. Walczak, C. Ancuța, I. Ancuta, A. Balanescu, F. Berghea, S. Bojin, Mihaela Arvunescu, R. Ionescu, E. Mociran, M. Pavel, S. Rednic, Adriana Voie, C. Zainea, O. Bugrova, A. Demin, O. Ershova, I. Gavrisheva, D. Krechikova, Gennady Kuropatkin, I. Marusenko, I. Menshikova, S. Noskov, A. Rebrov, S. Smakotina, S. Yakushin, E. Zhilyaev, J. Ramos, F. García, A. Nebro, Silvia Esteban, Juan Bursón, Raimon Sala, Ş. Ataman, S. Hizmetli, O. Kuru, K. Douglas, P. Emery, V. Ong, T. Sheeran, R. Faraawi, Clode Lessard, C. Mendoza, H. Ávila-Armengol, F. Zapata, F. Irazoque-Palazuelos, Marco Ceceña, C. Pacheco-Tena, Juan Rizo-Rodríguez, Isaura Rodríguez-Torres, J. Aelion, B. Caciolo, James Calmes, Prem Chatpar, Nimesh Dayal, A. Jesus, A. Dikranian, E. Diri, Michael Fairfax, Ira Fenton, R. Fleischmann, N. Gaylis, R. George, D. Halter, P. Hernandez, Susan Hole, Antony Hou, J. Huff, S. Kafaja, A. Kennedy, H. Kenney, S. Kimmel, Brian Kirby, C. Legerton, S. Lindsey, J. Mallepalli, Steven Mathews, S. Metyas, W. Mizutani, Sabeen Najam, J. Nascimento, Shirley Pang, Rakesh Patel, J. Poiley, C. Ramírez, Riteesha Reddy, Q. Rehman, W. Schnitz, C. Scoville, W. Shergy, J. Silverfield, A. Singhal, Yvonne Smallwood-Sherrer, S. Songcharoen, M. Stack, W. Stohl, T. Su, J. Udell, Saleema Waraich, Charles Weidmann, N. Wei, C. Wiesenhutter, A. Winkler, Karen Zagar, A. Berman, E. Mysler, R. Hidalgo, H. Venarotti, Irmgadt Sariego, Renato Calabresse, Juan Ruiz-Tagle, Luis Vargas, A. Berrocal, M. Portocarrero, Felix Jesus, Romero Pena (2017)
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialThe Lancet, 390
-
M. Prevoo, M. Hof, H. Kuper, M. Leeuwen, L. Putte, P. Riel (1995)
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis and rheumatism, 38 1
-
D. Furst, A. Pangan, L. Harrold, Hong Chang, G. Reed, J. Kremer, J. Greenberg (2011)
Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registryArthritis Care & Research, 63
-
P. Taylor, M. Weinblatt, G. Burmester, Terence Rooney, S. Witt, C. Walls, M. Issa, C. Salinas, Chadi Saifan, X. Zhang, A. Cardoso, M. González-Gay, T. Takeuchi (2019)
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid ArthritisArthritis & Rheumatology (Hoboken, N.j.), 71
-
D. Heijde, M. Hof, P. Riel, M. Leeuwen, M. Rijswijk, L. Putte (1992)
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.Annals of the Rheumatic Diseases, 51
-
M. Schiff, M. Weinblatt, R. Valente, D. Heijde, G. Citera, A. Elegbe, M. Maldonado, R. Fleischmann (2013)
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialAnnals of the Rheumatic Diseases, 73
-
J. O’Shea, D. Schwartz, A. Villarino, M. Gadina, I. McInnes, A. Laurence (2015)
The JAK-STAT pathway: impact on human disease and therapeutic intervention.Annual review of medicine, 66
-
D. Cella, S. Yount, M. Sorensen, E. Chartash, N. Sengupta, J. Grober (2005)
Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.The Journal of rheumatology, 32 5
-
J. Kremer, P. Emery, H. Camp, A. Friedman, Li Wang, A. Othman, N. Khan, A. Pangan, S. Jungerwirth, E. Keystone (2016)
A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor TherapyArthritis & Rheumatology (Hoboken, N.j.), 68
-
J. Smolen, D. Aletaha, J. Bijlsma, F. Breedveld, D. Boumpas, G. Burmester, B. Combe, M. Cutolo, M. Wit, M. Dougados, P. Emery, A. Gibofsky, J. Gómez-Reino, B. Haraoui, J. Kalden, E. Keystone, T. Kvien, I. McInnes, E. Martı́n-Mola, C. Montecucco, M. Schoels, D. Heijde (2010)
Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 69
-
M. Genovese, J. Smolen, M. Weinblatt, G. Burmester, S. Meerwein, H. Camp, Li Wang, A. Othman, N. Khan, A. Pangan, S. Jungerwirth (2016)
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateArthritis & Rheumatology (Hoboken, N.j.), 68
-
J. Smolen, R. Landewé, F. Breedveld, M. Dougados, P. Emery, C. Gaujoux-Viala, S. Gorter, R. Knevel, J. Nam, M. Schoels, D. Aletaha, M. Buch, L. Gossec, T. Huizinga, J. Bijlsma, G. Burmester, B. Combe, M. Cutolo, C. Gabay, J. Gómez-Reino, M. Kouloumas, T. Kvien, E. Martı́n-Mola, I. McInnes, K. Pavelka, P. Riel, Marieke Scholte, D. Scott, T. Sokka, G. Valesini, R. Vollenhoven, K. Winthrop, J. Wong, A. Zink, D. Heijde (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 69
-
P. Taylor, B. Zhu, C. Gaich, X. Zhang, A. DeLozier, D. Schlichting, H. Patel, F. Durand, B. Fautrel (2017)
SAT0055 Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 76
-
T. Heiberg, T. Kvien (2002)
Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority.Arthritis and rheumatism, 47 4
-
C. Ketfi, Alexandre Boutigny, N. Mohamedi, Sara Bouajil, Benjamin Magnan, G. Amah, J. Dillinger (2020)
Risk of Venous Thromboembolism in Rheumatoid Arthritis.Joint bone spine
-
V. Strand, D. Khanna (2010)
The impact of rheumatoid arthritis and treatment on patients' lives.Clinical and experimental rheumatology, 28 3 Suppl 59
-
M. Genovese, J. Kremer, O. Zamani, C. Ludivico, M. Krogulec, L. Xie, S. Beattie, A. Koch, T. Cardillo, Terence Rooney, W. Macias, S. Bono, D. Schlichting, J. Smolen (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis.The New England journal of medicine, 374 13
-
D. Aletaha, T. Neogi, A. Silman, J. Funovits, D. Felson, C. Bingham, N. Birnbaum, G. Burmester, V. Bykerk, M. Cohen, B. Combe, K. Costenbader, M. Dougados, P. Emery, G. Ferraccioli, J. Hazes, K. Hobbs, T. Huizinga, A. Kavanaugh, J. Kay, T. Kvien, T. Laing, P. Mease, H. Ménard, L. Moreland, R. Naden, T. Pincus, J. Smolen, E. Stanisławska-Biernat, D. Symmons, P. Tak, K. Upchurch, J. Vencovský, F. Wolfe, G. Hawker (2010)
2010 Rheumatoid arthritis classifi cation criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative -
(2013)
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid ArthritisAnnals of Internal Medicine, 159
-
D. Felson, Jennifer Anderson (1995)
Methodological and statistical approaches to criteria development in rheumatic diseases.Bailliere's clinical rheumatology, 9 2
-
J. Nam, S. Ramiro, C. Gaujoux-Viala, K. Takase, Mario Leon-Garcia, P. Emery, L. Gossec, R. Landewé, J. Smolen, M. Buch (2014)
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 73
-
D. Heijde, Yoshiya Tanaka, R. Fleischmann, E. Keystone, J. Kremer, C. Zerbini, M. Cardiel, S. Cohen, P. Nash, Y. Song, D. Tegzová, B. Wyman, D. Gruben, B. Benda, G. Wallenstein, S. Krishnaswami, S. Zwillich, J. Bradley, C. Connell (2013)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.Arthritis and rheumatism, 65 3
-
Hyon Choi, Y. Rho, Yanyan Zhu, L. Cea-Soriano, J. Aviña-Zubieta, Yuqing Zhang (2012)
The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort studyAnnals of the Rheumatic Diseases, 72
-
Seoyoung Kim, S. Schneeweiss, Jun Liu, D. Solomon (2013)
Risk of Venous Thromboembolism in Patients With Rheumatoid ArthritisArthritis Care & Research, 65
-
C. Charles-Schoeman, R. Fleischmann, J. Davignon, H. Schwartz, S. Turner, C. Beysen, M. Milad, M. Hellerstein, Zhen Luo, I. Kaplan, R. Riese, A. Zuckerman, I. McInnes (2015)
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡Arthritis & Rheumatology (Hoboken, N.j.), 67
- Publisher
- Wiley
- Copyright
- © 2019, American College of Rheumatology
- ISSN
- 2326-5191
- eISSN
- 2326-5205
- DOI
- 10.1002/art.41032
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Arthritis & Rheumatology – Wiley
Published: Nov 1, 2019